Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721488 | 1.00 | CXCR4 (0.47) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL6578361 | 1.00 | CXCR4 (0.47) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL25633044 | 0.97 | — | — | |
| SCHEMBL10708212 | 0.87 | HIF1A (0.50) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL350591 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL20544691 | 0.79 | — | — | |
| SCHEMBL15355221 | 0.75 | CXCR4 (0.47) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL12100700 | 0.71 | — | — | |
| SCHEMBL12882833 | 0.71 | CXCR4 (0.41) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL138572 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| EP-1112255-B1 | 4,4-BIARYLPIPERIDINE DERIVATIVES WITH OPIOID RECEPTOR ACTIVITY | PFIZER PROD INC (US) | 2005-12-14 | — | — | EP | disclosed |
| US-6960609-B2 | 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands | PFIZER, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-6514975-B1 | Tetrazoles as selective agonists for the delta opioid receptor | PFIZER INC | 2003-02-04 | — | — | US | disclosed |
| EP-1279666-A1 | 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands | Pfizer Products Inc. (US) | 2003-01-29 | — | — | EP | disclosed |
| US-6503905-B1 | Treating nervous system and gastrointestinal disorders; analgesics, antiasthmatics | PFIZER INC | 2003-01-07 | — | — | US | disclosed |
| EP-1262196-A2 | Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence | Pfizer Products Inc. (US) | 2002-12-04 | — | — | EP | disclosed |
| US-6444679-B1 | NEUROLOGICAL AND GASTROINTESTINAL DISORDERS; DELTA OPIOID LIGANDS OR OPIOID RECEPTORS | PFIZER INC | 2002-09-03 | — | — | US | disclosed |
| US-20020077323-A1 | Use of delta opioid receptor ligands and serotonin reuptake inhibitors in the treatment of chemical dependencies | PFIZER INC. | 2002-06-20 | — | — | US | disclosed |
| US-20020013321-A1 | 4,4-Biarylpiperidine derivatives | PFIZER INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1140835-A1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | Pfizer Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1038872-A1 | 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands | Pfizer Products Inc. (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-2000039091-A1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | CXCR4 234/4885SMN1; SMN2 1660/4885ALDH1A1 3923/4885 |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | CXCR4 565/4885SMN1; SMN2 3066/4885ALDH1A1 1054/4885 |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | CXCR4 565/4885SMN1; SMN2 3066/4885ALDH1A1 1054/4885 |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | CXCR4 234/4885SMN1; SMN2 1660/4885ALDH1A1 3923/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | CXCR4 183/4885SMN1; SMN2 997/4885ALDH1A1 4177/4885 |
| US-20020013321-A1 | 4,4-Biarylpiperidine derivatives | CYP4B1, CYP3A5, CYP3A4 | CXCR4 1172/4885SMN1; SMN2 225/4885ALDH1A1 178/4885 |
| US-20020077323-A1 | Use of delta opioid receptor ligands and serotonin reuptake inhibitors in the treatment of chemical dependencies | OPRM1, OPRD1, OPRK1 | CXCR4 514/4885SMN1; SMN2 1995/4885ALDH1A1 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.